Galectin Therapeutics Inc.
GALTGalectin Therapeutics Inc. (GALT) is a biotechnology company focused on developing therapies that target galectin proteins, which play a role in fibrosis, inflammation, and cancer. Their primary pathways involve developing drugs to treat various fibrotic and immune-related conditions, including non-alcoholic steatohepatitis (NASH) and other liver diseases. The company leverages its expertise in galectin biology to advance novel therapeutics aimed at addressing unmet medical needs.
Company News
Galectin Therapeutics reported Q3 2025 financial results, highlighting promising biomarker data from the NAVIGATE trial for belapectin in treating MASH cirrhosis. The company submitted data to the FDA and is seeking guidance on next steps, with encouraging results showing potential disease progression reduction.
Galectin Therapeutics is hosting a virtual event to discuss its drug belapectin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The event will feature key opinion leaders and highlight results from the company's NAVIGATE Phase 3 clinical trial.
Galectin Therapeutics announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented at the 2025 MASH-TAG Conference. The company's executive leadership will also host one-on-one meetings during the JP Morgan Healthcare Conference to discuss the NAVIGATE topline results and the ...
Galectin Therapeutics reported financial results for Q2 2024, with a net loss of $12.4 million. The company's lead drug, belapectin, is in a Phase 2b/3 trial for the treatment of MASH-related liver cirrhosis, with interim data expected in December 2024.
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy.
